Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial
Abstract
Abastract Purpose A post hoc analysis of data from a previously published clinical trial was conducted using the desirability of outcome ranking (DOOR) methodology with the aim provide additional information on the use of fosfomycin for the treatment of bacteraemic urinary tract infection (BUTI) caused by multi-drug-resistant (MDR) E. coli. Methods Three DOOR systems with five, six and seven categories, respectively were developed. Safety and efficacy were prioritised in all rankings, but step down to oral therapy and exposure to antibiotics with lower ecological impact were also considered in DOOR-6 and DOOR-7. The probability that a patients assigned to fosfomycin was classified into a more desirable outcome category was calculated for the three DOOR definitions. Subgroups analyses and an ordinal logistic regression model were also performed. Results Data from 143 participants were analysed. The probability of having a more desirable outcome after treatment with fosfomycin versus the comparators was 0.44 (95% CI 0.36 − 0.52) for DOOR-5; 0.50 (95% IC 0.42 − 0.58) using DOOR-6 and 0.61 (95% CI 0.53–0.69) with DOOR-7. In subgroups, the highest probability of having a better DOOR with fosfomycin was seen in the clinically evaluable population and among patients without chronic heart disease or renal insufficiency for the DOOR-7 definition. Conclusions DOOR analysis could be applied to the FOREST trial data; the results were somehow different for the different DOOR systems…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.